Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.
Lim SH. et al, (2021), Lancet Haematol, 8, e542 - e544
Limited-stage diffuse large B-cell lymphoma: current management and challenges.
Zhang X-Y. et al, (2021), Br J Haematol, 194, 508 - 517
Sequencing therapies in Hodgkin lymphoma.
Phillips EH. et al, (2021), Lancet Haematol, 8, e537 - e539
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Alderuccio JP. et al, (2021), Blood Adv, 5, 2852 - 2862
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N. et al, (2021), Adv Ther, 38, 3789 - 3802
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M. et al, (2021), Lancet Haematol, 8, e433 - e445
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
Crosswell HE. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA. et al, (2021), Blood Adv, 5, 2229 - 2236
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ. et al, (2021), J Clin Oncol, 39, 1129 - 1138
Care of haematology patients in an overwhelmed healthcare system.
Willan J. et al, (2021), Br J Haematol, 193, 269 - 270
Modification of escalated beacopp with dacarbazine substitution reduces toxicity while maintaining efficacy for the treatment of advanced-stage Hodgkin lymphoma
Santarsieri A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 40 - 41
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A. et al, (2021), Br J Haematol, 193, 63 - 71
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients With Relapsed or Refractory Hodgkin Lymphoma
Herrera AF. et al, (2021), CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 19, 13 - 14
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.
Rampotas A. et al, (2021), Ther Adv Hematol, 12
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Straus D. et al, (2020), Leuk Lymphoma, 61, 2931 - 2938
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Noy A. et al, (2020), Blood Adv, 4, 5773 - 5784
Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma.
Djebbari F. et al, (2020), Eur J Haematol, 105, 667 - 671
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
Lee LYW. et al, (2020), Lancet Oncol, 21, 1309 - 1316